Physician profile
Mark A Liska
NPI 1538191846
$7,599.39
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,461 · 2020: $911 · 2021: $1,391 · 2022: $1,718 · 2023: $2,039 · 2024: $80.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,044 · Education: $54.99 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,043.70 |
| Education | $54.99 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,696.76 | 2019-2024 | |
| Janssen Biotech, INC. | $972.58 | 2019-2023 | Tremfya, Simponi, Simponi Aria |
| Amgen INC. | $709.53 | 2019-2023 | Otezla |
| Genzyme Corporation | $617.62 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $576.13 | 2019-2023 | |
| Lilly USA, LLC | $561.45 | 2019-2023 | Taltz, Olumiant |
| Janssen Scientific Affairs, LLC | $374.99 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $299.28 | 2022-2023 | Sotyktu |
| Celgene Corporation | $250.71 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $191.48 | 2019-2023 | Dupixent, Libtayo |
| Ucb, INC. | $183.64 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $173.87 | 2020-2023 | Absorica Ld, Winlevi, Ilumya |
| Incyte Corporation | $170.14 | 2021-2023 | Opzelura |
| Pfizer INC. | $168.50 | 2019-2023 | |
| Leo Pharma INC. | $141.73 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $94.32 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $89.80 | 2020-2023 | Jublia |
| Allergan, INC. | $75.37 | 2019-2020 | |
| Dusa Pharmaceuticals, INC. | $69.72 | 2019 | |
| Blueprint Medicines Corporation | $47.94 | 2022-2023 | |
| Biofrontera INC. | $34.52 | 2021-2022 | |
| Galderma Laboratories, L.P. | $30.68 | 2020-2022 | |
| Arcutis Biotherapeutics, INC. | $23.60 | 2023 | |
| Dermira, INC. | $23.15 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.88 | 2023 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Liska listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.